Amisulpride - An Open Clinical Study of a New Benzamide in Schizophrenic Patients

Abstract

In pharmacological screening amisulpride produces no catalepsy, no inhibition of stereotypic movements, yet a blockade of drug-induced vomiting. During an open clinical trial lasting 4 weeks, 14 patients (13 schizophrenics) were treated with the compound. The (BPRS-) syndromes anxiety/depression, thought disorder, activity, hostility and the global score showed significant improvement. With the AMDP system significant changes were seen in the paranoid-hallucinatory, manic, depressive and hostility syndromes as well as in the global score. No changes were revealed in anergia (BPRS) and apathia (AMDP). In the EEG a significant decrease in the frequency of alpha-rhythms was found. The scores of the Simpson-scale for extrapyramidal side effects were low, but there was an acute dystonic reaction in one patient. In three cases akathisia occurred; biperiden administration was necessary three times. In conclusion, amisulpride showed good antipsychotic efficacy without sedation. Contrary to expectations based on the pharmacological screening, we did find extrapyramidal side effects.

Amisulpride Versus Haloperidol in Treatment of Schizophrenic Patients - Results of a Double-Blind Study

“…When the two medications were compared, the amisulpride group showed a beUer performance with respect to the antidepressant efTects. This result correlates with the results of numerous previous studies (Klein et al , 1983;Mann et al , 1984;Ziegler and Jesau, 1984). In addition, the amisulpride group revealed reduced manifestations of extrapyramidal side-efTects as measured by the Simpson and Webster scales.…”

“…Haloperidol appeared to generate more extrapyramidal side-effects. Mann et al (1984) examined amisulpride in an open clinical study of 13 schizophrenics. On the whole, amisulpride treatment proved effective: taken together, the BPRS syndrome-scores such as anxiety-depression, thought disturbance, activation or hostility showed significant improveme nt.…”

Pharmacological Management of Persistent Hostility and Aggression in Persons With Schizophrenia Spectrum Disorders: A Systematic Review

“…44,47,50,108,[114][115][116][117][118][119][120][121][122][123][124][125][126][127][128][129][130][131] ( Table 3) Twenty-five articles were identified that reported relevant data. One of these 101 was also reported in Table 1 because overt violence was an outcome measure.…”

Combination of Clozapine and Amisulpride in Treatment-Resistant Schizophrenia - Case Reports and Review of the Literature

“…Amisulpride has been shown to be an effective and safe atypical antipsychotic drug [13,27,28,33,39] and exhibits a unique pharmacological profile, which is characterized by a predominant interaction with D3/D2-dopamine receptors [41]. Amelioration of negative symptoms, even at a low dose (100 mg/day) [40], and absence of weight gain belong to the important advantages of this substance [26].…”